The content on this site is intended for healthcare professionals only

For the latest ecancer COVID-19 resources, click on this link

Breast

Prostate & urology

Lung & pleura

Colorectal & gastro

Melanoma & skin

Head & neck

Ovary & gynaecology

+ -

PSA/Prostate screening

2009 ASCO Annual Meeting

29 May - 2 Jun 2009

Published: 25 Jun 2009

Views: 13579

Rating:

Save

Dr. Otis W. Brawley - Chief Medical Officer, ASCO

Prostate cancer screening studies and ASCO 2009

Categories:
Prostate & urology

Related Videos

Advances in prostate cancer in the last 10 years and a glimpse to the future

Prof Laura-Maria Krabbe, Prof Karim Fizazi and Prof Johann De Bono

Advances in prostate cancer in the last 10 years and a glimpse to the future ( Prof Laura-Maria Krabbe, Prof Karim Fizazi and Prof Johann De Bono )

Quality of life and safety in novel therapies for prostate cancer

Prof Heather Payne, Prof Alicia Morgans and Prof Bertrand Tombal

Quality of life and safety in novel therapies for prostate cancer ( Prof Heather Payne, Prof Alicia Morgans and Prof Bertrand Tombal )

Enzalutamide plus androgen deprivation therapy prolongs survival in men with met...

Prof Andrew Armstrong - Duke University, Durham, USA

Enzalutamide plus androgen deprivation therapy prolongs survival in men with metastatic hormone-sensitive prostate cancer ( Prof Andrew Armstrong - Duke University, Durham, USA )

Adding abiraterone acetate plus prednisolone to standard therapy lengthens survi...

Prof Nick James - The Institute of Cancer Research, London, UK

Adding abiraterone acetate plus prednisolone to standard therapy lengthens survival in non-metastatic high-risk prostate cancer ( Prof Nick James - The Institute of Cancer Research, London, UK )

PARP inhibitors in prostate cancer: Case based testing and clinical decisions

Dr Neal Shore and Prof Fred Saad

PARP inhibitors in prostate cancer: Case based testing and clinical decisions ( Dr Neal Shore and Prof Fred Saad )

OncoAlert and ecancer - ESMO 2021 Day 4

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer - ESMO 2021 Day 4 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

Abiraterone acetate plus prednisolone added to ADT + docetaxel, gives 25% reduct...

Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France

Abiraterone acetate plus prednisolone added to ADT + docetaxel, gives 25% reduction in risk of death compared to ADT + docetaxel alone in prostate cancer ( Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France )

OncoAlert and ecancer - ESMO 2021 Day 3

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer - ESMO 2021 Day 3 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

High- vs low-dose pre-operative ipilimumab and nivolumab in locoregionally advan...

Dr Jeroen Van Dorp - Netherlands Cancer Institute, Amsterdam, The Netherlands

High- vs low-dose pre-operative ipilimumab and nivolumab in locoregionally advanced urothelial cancer ( Dr Jeroen Van Dorp - Netherlands Cancer Institute, Amsterdam, The Netherlands )

More from ecancer